Nothing Special   »   [go: up one dir, main page]

IN2014MN01568A - - Google Patents

Info

Publication number
IN2014MN01568A
IN2014MN01568A IN1568MUN2014A IN2014MN01568A IN 2014MN01568 A IN2014MN01568 A IN 2014MN01568A IN 1568MUN2014 A IN1568MUN2014 A IN 1568MUN2014A IN 2014MN01568 A IN2014MN01568 A IN 2014MN01568A
Authority
IN
India
Prior art keywords
dose
rasagiline
pramipexole
subtherapeutic
fixed
Prior art date
Application number
Inventor
Nurit Livnah
Pninit Litman
Sarit Zaksh
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48781101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01568(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of IN2014MN01568A publication Critical patent/IN2014MN01568A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition for use in treatment of Parkinson s disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline and the dose of pramipexole is lower than or equal to the dose of rasagiline.
IN1568MUN2014 2012-01-12 2013-01-10 IN2014MN01568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585824P 2012-01-12 2012-01-12
PCT/IL2013/050025 WO2013105092A1 (en) 2012-01-12 2013-01-10 Fixed dose combination therapy of parkinson's disease

Publications (1)

Publication Number Publication Date
IN2014MN01568A true IN2014MN01568A (en) 2015-05-08

Family

ID=48781101

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1568MUN2014 IN2014MN01568A (en) 2012-01-12 2013-01-10

Country Status (22)

Country Link
US (1) US20150079187A1 (en)
EP (1) EP2802319B1 (en)
JP (1) JP6243351B2 (en)
KR (2) KR20200013791A (en)
CN (1) CN104168896B (en)
AU (1) AU2013208653B2 (en)
CA (1) CA2860952C (en)
CY (1) CY1119793T1 (en)
DK (1) DK2802319T3 (en)
ES (1) ES2655676T3 (en)
HK (1) HK1203847A1 (en)
HU (1) HUE038029T2 (en)
IL (1) IL233572B (en)
IN (1) IN2014MN01568A (en)
LT (1) LT2802319T (en)
MX (1) MX360409B (en)
NO (2) NO2802319T3 (en)
PL (1) PL2802319T3 (en)
PT (1) PT2802319T (en)
RS (1) RS56742B1 (en)
RU (1) RU2642962C9 (en)
WO (1) WO2013105092A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367565A (en) * 2014-11-21 2015-02-25 哈尔滨圣吉药业股份有限公司 Pramipexole dihydrochloride sustained release pellets
CN105147627B (en) * 2015-08-19 2019-04-12 天津红日药业股份有限公司 A kind of pharmaceutical composition and preparation method thereof containing body of Pramipexole dihydrochloride
US11234961B2 (en) * 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
US20220064204A1 (en) * 2018-12-19 2022-03-03 Galecto Biotech Ab Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside
CN112915083A (en) * 2019-12-06 2021-06-08 上海医药集团股份有限公司 Pharmaceutical composition, kit of parts and application thereof
WO2023112024A1 (en) * 2021-12-14 2023-06-22 Pharma Two B Ltd. Method of treating parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477178A1 (en) * 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
JP2007523122A (en) * 2004-02-20 2007-08-16 ノバルティス アクチエンゲゼルシャフト DPP-IV inhibitors for the treatment of neurodegenerative and cognitive disorders
AU2005269416B2 (en) 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
KR101613749B1 (en) * 2008-06-06 2016-04-19 파마 투 비 엘티디 Pharmaceutical Compositions for Treatment of Parkinson's disease
CN102186350A (en) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 Compositions and methods of using (r)-pramipexole
DK2531181T3 (en) 2010-02-03 2019-07-15 Pharma Two B Ltd FORMULATIONS OF RASAGILIN WITH EXTENDED DELIVERY AND USES THEREOF

Also Published As

Publication number Publication date
WO2013105092A1 (en) 2013-07-18
RU2017146994A3 (en) 2021-03-16
RS56742B1 (en) 2018-03-30
CA2860952C (en) 2020-09-15
PL2802319T3 (en) 2018-04-30
IL233572B (en) 2020-05-31
KR102276896B1 (en) 2021-07-14
EP2802319A4 (en) 2015-07-01
KR20200013791A (en) 2020-02-07
RU2771522C2 (en) 2022-05-05
IL233572A0 (en) 2014-08-31
CA2860952A1 (en) 2013-07-18
AU2013208653A1 (en) 2014-08-28
JP6243351B2 (en) 2017-12-06
RU2642962C2 (en) 2018-01-29
KR20140138629A (en) 2014-12-04
HUE038029T2 (en) 2018-09-28
RU2014132940A (en) 2016-02-27
MX2014008537A (en) 2014-11-25
CY1119793T1 (en) 2018-06-27
HK1203847A1 (en) 2015-11-06
US20150079187A1 (en) 2015-03-19
LT2802319T (en) 2018-04-10
CN104168896B (en) 2018-08-10
EP2802319A1 (en) 2014-11-19
JP2015508411A (en) 2015-03-19
PT2802319T (en) 2018-01-29
NO2802319T3 (en) 2018-03-24
ES2655676T3 (en) 2018-02-21
RU2017146994A (en) 2018-10-22
NO2901008T3 (en) 2018-08-04
MX360409B (en) 2018-10-30
EP2802319B1 (en) 2017-10-25
AU2013208653B2 (en) 2017-04-20
CN104168896A (en) 2014-11-26
RU2642962C9 (en) 2018-05-04
DK2802319T3 (en) 2018-01-29

Similar Documents

Publication Publication Date Title
IL253225B (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IL239488A0 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
IN2012DN06720A (en)
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
NZ702663A (en) Nuclear transport modulators and uses thereof
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
GB201111485D0 (en) Drug composition and its use in therapy
IL232764A (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease
IN2014MN01568A (en)
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
IL260078B (en) Therapy for use for the treatment of gaucher's disease
CO7101244A2 (en) Substituted phenylimidazopyrazoles and their use
GB201115977D0 (en) Neurodevelopmental disorders
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
UA77604U (en) 1,2,4-triazole derivative exhibiting actoprotective activity
NZ623275A (en) Treatment of ocular disease
UA53217U (en) Mask for therapy and general health improvement
UA94528C2 (en) use of glucosamine derivatives as cerebral protective agents
PL397528A1 (en) Dynamic and stimulating corset for the treatment of Schumann disease